AI Trends

Google-affiliated AI drug discovery company Isomorphic Labs completes $5 billion Series C funding

Phoenix TechnologyUpdated Nov 18 14:57

AI summary

Google-affiliated AI drug discovery company Isomorphic Labs announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest on a large scale, setting a new global record for a single funding round in the AI drug discovery field. The company's cumulative publicly disclosed funding has reached $7.7 billion, and its proprietary drug design engine IsoDDE combines simulation models and agents to advance multiple candidate drug pipelines. Hassabis previously stated that the first clinical trials are expected to begin before the end of 2026, a timeline that has been delayed from the original target of the end of 2025.

Why read this

AI score 65

The $5 billion Series C funding sets a new single-round record for AI drug discovery, offering readers insight into the gap between capital bets and clinical trial timelines.

Topics

Tags

Body · AI translation

Google-affiliated company secures largest single-round financing in AI pharma

Yicai November 18, 2026, 14:11:52, from Beijing

Word count: 1,655; reading time: about 3 minutes

Author | Yicai Liu Xiaojie

On November 17 local time, Google-affiliated AI pharma company Isomorphic Labs announced the completion of a $5 billion (about RMB 35.5 billion) Series C financing, co-led by Greenoaks and Sequoia Capital, with new investors including a16z participating, while Google parent Alphabet continued to invest on a large scale. Existing investors including Temasek, Thrive Capital and MGX also participated.

This round set a new record for the largest single-round financing in the global AI pharma field, coming only half a year after Isomorphic Labs' previous round. In May this year, the company had just secured a $2.1 billion Series B financing, which at the time also set a record for a single financing in the global AI pharma industry. Together with the $600 million first external financing completed in March 2025, this company, founded only five years ago, has disclosed cumulative financing of $7.7 billion.

Isomorphic Labs was founded in the UK by Nobel Prize in Chemistry laureate and former Google DeepMind co-founder Demis Hassabis. The company was spun out of Google DeepMind in 2021, with Hassabis serving as CEO. In August this year, after Hassabis stepped down as CEO of Google DeepMind, he focused on the long-term AGI strategy, AI's social impact and this AI pharma company Isomorphic Labs.

Why are investors willing to pour huge sums into an AI company that has no marketed drug yet? For Hassabis, this is the next major scientific breakthrough he is trying to achieve with AI after AlphaFold successfully predicted protein structures.

Traditional new drug R&D is a long and expensive process. Researchers need to search through massive numbers of compounds for potentially effective candidate molecules, then optimize their efficacy, safety and other characteristics through repeated experiments. Even after entering clinical trials, the risk of eventual failure remains high.

Isomorphic Labs hopes to greatly improve the efficiency of this process through AI. Its core technology is the proprietary drug design engine IsoDDE, which integrates a series of foundational simulation AI models covering multiple therapeutic areas and different drug types, capable of exploring chemical space and helping R&D teams design, screen and optimize molecules with desirable drug-like properties.

In addition to simulation models, the company has also developed proprietary agents for exploring complex biological systems and conducting reasoning. Isomorphic Labs says that combining models with agents has driven progress in pipelines of multiple types of candidate drugs. At present, the company's internal oncology and immunology projects as well as partnered projects have achieved preclinical results.

Isomorphic Labs said it has established R&D partnerships with large pharmaceutical companies such as Novartis, Eli Lilly and Johnson & Johnson to explore the application of AI in different drug R&D projects.

In a blog post, Hassabis mentioned that when Isomorphic Labs was founded, the team believed biology could be understood and modeled at the most fundamental molecular level, and that AI could significantly accelerate this process. According to him, this round of financing will help the company further develop foundational biology models, increase understanding of disease mechanisms, and push the first therapeutic programs into clinical trials to provide patients with a new generation of drugs.

However, in contrast to the huge financing, Isomorphic Labs still has a long way to go before launching a drug that can be sold on the market.

In January this year, Hassabis said at the World Economic Forum in Davos that the company expected to launch its first clinical trials by the end of 2026. This timetable has already been delayed from the previously proposed target of the end of 2025.

This is also the core problem that the AI pharma industry has not yet solved: although AI can accelerate the discovery of drug molecules, whether these molecules can become safe and effective drugs still requires lengthy verification. Drug R&D must not only prove that it can treat human diseases, but also ensure that it does not produce major side effects.

Some industry practitioners believe that although the AI drug R&D field has huge capital bets, the risk of clinical trial failure remains high, "because huge amounts of money cannot guarantee the launch of market-ready drugs." Improved model predictive capability does not mean that the entire clinical R&D cycle can be shortened proportionally.

Isomorphic Labs is undergoing another form of commercialization test in the AI industry. Over the past few years, the market has been accustomed to evaluating the value of AI companies through model rankings, generation speed and user scale. But in the pharmaceutical field, model performance is only the starting point; ultimately, clinical trial results are needed to prove the actual value of the technology.

Compared with "half of the timeline being spent on spending billions of dollars to make chatbots more interesting," some netizens believe that $5 billion spent on tackling diseases seems more worthy of attention. If AI's first truly killer application is not an app but a drug, that is the plot twist he has been expecting.

WeChat editor | Yulin

Source

Phoenix Technology